CRBU — Caribou Biosciences, Inc.

Nasdaq · Health Care · Biotechnology · CIK 1619856 ·
Last close
$1.64
Market Cap
$162.66M
52W High
$2.49
52W Low
$1.59
ADV30
1,839,388
Next earnings
2026-05-07
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 2,397,000 -26,280,000 -25,085,000 148,998,000 12,057,000 46,980,000
Dec 2025 3,941,000 -28,453,000 -26,488,000 175,367,000 12,360,000 53,192,000
Sep 2025 2,198,000 -29,400,000 -27,548,000 194,984,000 11,144,000 53,139,000
Jun 2025 2,667,000 -35,428,000 -54,098,000 220,903,000 25,201,000 54,771,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-110,992,000
Investing CF
$102,238,000
Financing CF
$4,821,000
CapEx
$-2,093,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.59
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-596,515,000
Inventory
Receivables
$2,979,000
ST Investments
$126,980,000
EBIT TTM
$-136,194,000
Pretax Income TTM
$-148,675,000
Interest Exp TTM
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$11,203,000
EBITDA
$-114,156,000
Free Cash Flow
$-63,509,124
Enterprise Value
$76,935,168
Total Cash
$117,626,000
Total Debt
$26,946,000
Shares Out
99,180,575
Trailing EPS
$-1.42
Book Value
$1.05
ROE
-83.5%
ROA
-34.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 11,159,000 -136,194,000 -148,125,000 175,367,000 53,192,000 -110,992,000
Dec 2024 9,994,000 -166,616,000 -149,105,000 313,313,000 60,362,000 -138,200,000
Dec 2023 34,477,000 -116,059,000 -102,070,000 432,209,000 63,808,000 -93,291,000
Dec 2022 13,851,000 -106,399,000 -99,421,000 373,765,000 72,894,000 -90,966,000

TTM Snapshot

Revenues TTM
$32,966,000
NetIncome TTM
$-92,307,000
OpCashFlow TTM
$0
Assets (Latest)
$313,313,000
Forward EPS
$-1.40

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.64 · call volume: 53 · put volume: 145
Expected Move to 2027-01-15: ±$0.92 (56.10%) — implied range $0.72$2.56 · ATM straddle on $1.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PLX Protalix BioTherapeutics, Inc. $162.75M $2.02
ABOS Acumen Pharmaceuticals, Inc. $162.51M $2.25
IPHA Innate Pharma SA $167.15M $1.78
DTIL PRECISION BIOSCIENCES INC $167.71M $6.50
IPHYF Innate Pharma SA $154.94M $1.65

News headlines (Yahoo Finance, 1h cache)

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
2026-06-11 12:01 · Yahoo
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
2026-06-11 12:00 · Yahoo
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
2026-06-09 10:04 · Yahoo
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows
2026-05-31 14:38 · Yahoo
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-27 20:05 · Yahoo
May 2026's Promising Penny Stocks
2026-05-14 12:04 · Yahoo
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-13 20:05 · Yahoo
Industry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts
2026-05-13 12:07 · Yahoo
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
2026-05-12 13:30 · Yahoo
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 23:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.